Angle plc (AGL) Ordinary 10p
1.50p
(1.28%)
- Add to watchlist
- Create an alert
- This stock can be held in a
1.50p
(1.28%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
1.50p
(1.28%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Angle agrees pharma services contract with new customer
28 July 2021 15:23
(Sharecast News) - Liquid biopsy company Angle has agreed a pharma services contract with another new customer, it announced on Wednesday, for its recently-established pharma services business.
-
Angle completes patient enrolment for ovarian cancer study
26 April 2021 11:38
(Sharecast News) - Liquid biopsy company Angle announced on Monday that its 200-patient ovarian cancer clinical verification study had completed patient enrolment.
-
Angle secures first large-scale pharma services contract
16 April 2021 12:31
(Sharecast News) - Liquid biopsy company Angle has secured its first large-scale pharma services contract, it announced on Friday.
-
Angle completes clinical labs in Guildford and Pennsylvania
30 March 2021 15:39
(Sharecast News) - Liquid biopsy company Angle has completed the fitout and staffing of its clinical services laboratories in Guildford and Pennsylvania, it announced on Tuesday.
-
Angle looks to raise up £20.0m via conditional placing
27 October 2020 09:26
(Sharecast News) - Liquid biopsy company Angle said on Tuesday that it was looking to raise up as much as £20.0m by way of a conditional placing of 43.47m new ordinary shares.
-
FDA accepts Angle's review submission for Parsortix PC1
20 October 2020 08:58
(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the US Food and Drug Administration (FDA) has completed its administrative review, and accepted the company's submission for...
-
Angle's Parsortix displays potential use for detection of immunotherapy efficacy
14 August 2020 09:21
(Sharecast News) - Liquid biopsy company Angle said on Friday that breakthrough research had shown the potential use of Parsortix to assess whether or not patients would respond to immunotherapy.
-
Angle's 'Parsortix' advantageous in breast cancer in new research
20 July 2020 10:16
(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting...
-
Angle upbeat on recent research using 'Parsortix'
12 May 2020 08:58
(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in...
-
Angle works with skeleton R&D crew during lockdown
28 April 2020 10:03
(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.
-
Angle UK, US, Canada operations 'severely disrupted' by Covid-19
31 March 2020 09:40
(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.
-
Angle upbeat on recent Parsortix research out of Italy
27 February 2020 12:42
(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its...
Company announcements Announcements
-
Notice of Interim Results and Webcast
7 September 2021 07:00
Angle
-
Director/PDMR Shareholding
24 August 2021 07:00
Angle
-
Issue of Equity
6 August 2021 13:17
Angle
-
Issue of Equity
3 August 2021 15:13
Angle
-
Contract secured for bespoke assay development
28 July 2021 07:00
Angle
-
Director/PDMR Shareholding
7 July 2021 18:34
Angle
-
Issue of Equity
2 July 2021 10:45
Angle
-
Result of AGM
30 June 2021 15:44
Angle
-
Result of Accelerated Bookbuild
25 June 2021 07:00
Angle
-
Accelerated bookbuild to raise up to £20m
24 June 2021 18:28
Angle
-
Annual General Meeting update
18 June 2021 11:42
Angle
-
Potential to prevent breast cancer relapse
1 June 2021 07:00
Angle
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.